The global infant clinical nutrition market size is estimated to grow from US$ 30.9 Bn in 2026 to US$ 46.8 Bn by 2033. The market is projected to record a CAGR of 6.1% during the forecast period from 2026 to 2033. The rise in preterm births, increasing neonatal intensive care admissions, and growing awareness of specialized infant nutrition.

North America leads due to advanced healthcare infrastructure and strong clinical nutrition adoption, while Asia-Pacific is the fastest-growing region, supported by improving healthcare access, rising birth rates, and increasing pediatric nutrition demand.

Driver: Increasing NICU Admissions and Specialized Infant Care

The rising number of premature and high-risk births globally is significantly increasing admissions to neonatal intensive care units (NICUs), which directly drives demand for infant clinical nutrition. According to the World Health Organization (WHO), approximately 13.4 million babies were born preterm in 2020, representing about 1 in 10 births worldwide. Preterm birth complications are also the leading cause of death among children under five, highlighting the need for specialized neonatal care and targeted nutritional support.

As NICU admissions increase, infants often require medically formulated nutrition to support growth, organ development, and immune function. Data from the U.S. National Vital Statistics System shows that NICU admission rates rose from 8.7% of births in 2016 to 9.8% in 2023, representing a 13% increase in admissions. Preterm and low-birth-weight infants are at least seven times more likely to require NICU care compared with full-term infants. These infants frequently rely on specialized enteral or oral clinical nutrition products designed for premature babies, increasing the demand for infant clinical nutrition solutions globally.

Restraint: High Cost of Specialized Infant Clinical Nutrition Products

The high cost associated with specialized infant clinical nutrition products is a major restraint for market growth, particularly in low- and middle-income countries. These products often include advanced ingredients such as hydrolyzed proteins, human milk oligosaccharides (HMOs), and micronutrient fortifiers, which increase manufacturing costs. In addition, infants requiring specialized nutrition frequently remain in neonatal intensive care units, where treatment expenses are already substantial. Reports indicate that NICU treatment costs can range from $3,000 to over $50,000 per infant depending on complexity and duration of care, placing significant financial pressure on families and healthcare systems.

Cost barriers can limit accessibility to advanced clinical nutrition products, particularly in regions with limited healthcare coverage or insurance support. According to global neonatal health studies, low-income countries experience significantly lower survival rates among extremely preterm infants, partly due to limited access to advanced medical care and specialized nutrition. In many healthcare systems, these specialized formulas and nutritional interventions are not fully reimbursed, forcing hospitals or caregivers to bear the costs. Consequently, economic constraints and unequal healthcare access can restrict adoption of specialized infant clinical nutrition products.

Opportunity: Development of Probiotic and HMO-Fortified Infant Nutrition

Advancements in infant nutrition science are creating major opportunities for the development of formulas fortified with probiotics and human milk oligosaccharides (HMOs). These ingredients aim to replicate the beneficial components of breast milk that support infant immune development and gut microbiota. Research in neonatal care has shown that probiotic supplementation in premature infants can significantly improve intestinal health and reduce severe complications. Studies indicate that probiotic use in NICU infants has been associated with approximately a 30% reduction in necrotizing enterocolitis (NEC), a life-threatening intestinal disease affecting preterm babies.

The opportunity for innovative infant clinical nutrition products is further supported by the large global population of premature infants requiring specialized feeding. With over 13 million preterm births annually worldwide, a significant proportion of infants require nutritional interventions beyond standard breastfeeding to ensure adequate growth and development. HMOs and probiotic-fortified formulas are increasingly being researched to mimic the biological functions of breast milk, including immune protection and improved digestion. As neonatal care continues to advance, demand for these next-generation nutritional formulations is expected to expand rapidly across hospitals and pediatric care settings

By Product Type Insights

Milk-based products dominate the infant clinical nutrition market with a 71.5% share in 2026 because they closely replicate the nutritional composition of human breast milk and provide essential nutrients required for early infant growth and development. These formulas contain balanced levels of proteins, fats, carbohydrates, vitamins, and minerals that support brain development, immunity, and healthy weight gain. Healthcare providers widely recommend milk-based formulas when breastfeeding is not possible or insufficient. According to the World Health Organization (WHO), breast milk is the optimal source of infant nutrition, but alternatives such as fortified milk-based formulas are commonly used when breastfeeding cannot fully meet nutritional needs.

Globally, only about 44% of infants under six months are exclusively breastfed, meaning a large proportion require supplemental nutrition. Since most available formulas are cow-milk-based or modified dairy formulas, they account for the largest share of infant clinical nutrition products used in hospitals, neonatal intensive care units (NICUs), and households worldwide, supporting strong market dominance globally.

By Route of Administration Insights

Oral administration dominates the infant clinical nutrition market because it is the most natural and preferred feeding method for infants. Breastfeeding or bottle-feeding supports normal sucking and swallowing reflexes while helping the gastrointestinal system develop properly. Medical guidelines recommend oral feeding whenever possible because it promotes digestive health and minimizes complications associated with invasive feeding methods. As a result, most infants receive nutrition through oral routes in both home settings and healthcare facilities.

According to neonatal care studies, infants in neonatal intensive care units are transitioned to oral feeding as soon as they become medically stable to encourage normal growth and feeding behavior. Intravenous nutrition is typically reserved only for critically ill infants who cannot tolerate food through the digestive system. Because most infants can safely consume nutrition orally, this route accounts for the largest share of infant clinical nutrition delivery worldwide today.

North America Infant Clinical Nutrition Market Trends

North America dominates the infant clinical nutrition market due to advanced healthcare infrastructure, high neonatal care capacity, and strong adoption of specialized infant nutrition products. The region has well-established neonatal intensive care units (NICUs) and high healthcare spending, which supports the use of clinical nutrition for premature and medically vulnerable infants. According to the U.S. Centers for Disease Control and Prevention (CDC), about 10.4% of births in the United States were preterm in 2022, representing more than 380,000 premature births annually. Premature infants often require specialized nutritional support to promote growth and organ development.

Additionally, North America has strong pediatric healthcare systems and widespread access to clinical nutrition products. Data from the CDC National Center for Health Statistics indicates that around 8–10% of newborns in the United States require NICU care, where medically formulated nutrition is frequently used. The presence of major infant nutrition manufacturers and high awareness of pediatric nutrition further contribute to the region’s dominant position in the infant clinical nutrition market.

Europe Infant Clinical Nutrition Market Trends

Europe represents an important region in the infant clinical nutrition market due to strong public healthcare systems, high awareness of infant nutrition, and supportive government health policies. Many European countries have universal healthcare coverage that supports neonatal care and specialized nutrition for infants requiring medical attention. According to Eurostat, the European Union recorded approximately 3.9 million births in 2022, creating substantial demand for infant nutrition products and neonatal healthcare services. In addition, several countries in the region have well-established neonatal care facilities that support the use of specialized infant nutrition.

Public health initiatives also encourage early nutritional intervention for premature and low-birth-weight infants. Data from the European Perinatal Health Report indicates that preterm births account for around 7–8% of all births across Europe, highlighting the need for specialized neonatal nutrition. With strong healthcare infrastructure and high standards for infant care, Europe remains a significant contributor to the global infant clinical nutrition market.

Asia-Pacific Infant Clinical Nutrition Market Trends

Asia-Pacific is the fast-growing market for infant clinical nutrition due to its large birth population, improving healthcare infrastructure, and increasing awareness of infant health and nutrition. Countries such as China and India account for a substantial proportion of global births, which drives demand for infant nutrition products. According to the United Nations Population Division, India recorded around 23 million births in 2022, the highest number globally, while China recorded more than 9 million births in the same year. The large newborn population significantly increases the need for infant healthcare and nutrition support.

The region is also experiencing improvements in neonatal healthcare services. Data from the World Health Organization (WHO) shows that Asia accounts for a large share of global preterm births, contributing to the need for specialized infant nutrition in hospitals and neonatal units. Rising healthcare investments, expanding hospital infrastructure, and increasing parental awareness about infant nutrition are accelerating market growth across Asia Pacific.

The infant clinical nutrition market is highly competitive, led by major nutrition companies such as Abbott Laboratories, Nestlé S.A., Danone, Reckitt Benckiser, and Fresenius SE & Co. KGaA. These players focus on developing advanced infant formulas, expanding pediatric nutrition portfolios, investing in research, and strengthening global distribution to support neonatal and infant health.

Key Industry Developments:  

• In September 2024, Perrigo announced a partnership between its Good Start® and Dr. Brown’s® brands and launched a new infant formula portfolio. The collaboration aimed to expand Perrigo’s presence in the infant nutrition market by offering a broader range of formula options for infants, including specialized and standard products.